Folliculitis decalvans

{{Infobox medical condition (new)

{{Infobox medical condition

| name = Folliculitis decalvans

| name = Folliculitis decalvans

| synonyms =

| synonyms =

| issue = 4

| issue = 4

| pages = 289–300

| pages = 289–300

| date = 2020

| year = 2020

| year = 2020

| language = English

| language = English

==Management==

==Management==

{{Empty section|date=April 2017}}

{{Empty section|date=April 2017}}

While there is no cure currently for Folliculitis Decalvans, there are treatments that have brought some patients ongoing relief from painful symptoms. One study available in the 'Journal of the American Academy of Dertmatology' indicates that of 23 patients, 21 of the study subjects with biopsy-proven FD found great relief with the Biologic Humira, citing picture and documented evidence. It is not yet known the full cause of the disease, but recent findings suggest an autoimmune component. In the vast majority of patients the bacteria Staphylococcus Aureus is present and has had minor success with a combination therapy of Clindamycin and Rifampin, although the rate of relief after this therapy is stopped is unknown. To date, Humira shows the best long-term therapeutic relief for patients with this painful disease that causes pustules, hair loss and excessive inflammation.

While there is no cure currently for Folliculitis Decalvans, there are treatments that have brought some patients ongoing relief from painful symptoms. One study available in the 'Journal of the American Academy of Dertmatology' indicates that of 23 patients, 21 of the study subjects with biopsy-proven FD found great relief with the Biologic Humira, citing picture and documented evidence. It is not yet known the full cause of the disease, but recent findings suggest an autoimmune component. In the vast majority of patients the bacteria Staphylococcus Aureus is present and has had minor success with a combination therapy of Clindamycin and Rifampin, although the rate of relief after this therapy is stopped is unknown. To date, Humira shows the best long-term therapeutic relief for patients with this painful disease that causes pustules, hair loss and excessive inflammation.

Source: https://www.jaad.org/article/S0190-9622(22)00358-9/fulltext

Source: https://www.jaad.org/article/S0190-9622(22)00358-9/fulltext

== Epidemiology ==

== Epidemiology ==

This disorder was first described by [[Charles-Eugène Quinquaud]] in 1888. He isolated [[bacteria]] from the hair follicles of affected patients and introduced them in rats, mice and rabbits, with no result. In 1905 it was then differentiated from other scarring [[alopecia]]s and the name Folliculitis decalvans, that remains current, was introduced. About 11% of the occurrences of scarring alopecias are of this type. Men are more commonly affected than women and its appearance is usually between the late teens and middle adult years. According to studies in the [[United States]], [[African Americans]] are more frequently affected than [[White Americans]].{{cn|date=July 2022}}

This disorder was first described by [[Charles-Eugène Quinquaud]] in 1888. He isolated [[bacteria]] from the hair follicles of affected patients and introduced them in rats, mice and rabbits, with no result. In 1905 it was then differentiated from other scarring [[alopecia]]s and the name Folliculitis decalvans, that remains current, was introduced. About 11% of the occurrences of scarring alopecias are of this type. Men are more commonly affected than women and its appearance is usually between the late teens and middle adult years. According to studies in the [[United States]], [[African Americans]] are more frequently affected than [[White Americans]].{{citation needed|date=July 2022}}

==See also==

==See also==